Primary Analysis of Phase-2-Results for Cemiplimab in Patients (pts) with locally advanced Basal Cell Carcinoma (laBCC) who progress or cannot tolerate Hedgehog Inhibitors (HHI) Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Dutriaux, C., Kaatz, M., Lewis, K. D., Basset-Seguin, N., Chang, A. S., Dalle, S., Orland, A., Licitra, L., Robert, C., Ulrich, C., Hauschild, A., Migden, M. R., Dummer, R., Li, S., Bowler, T., Fury, M. G. WILEY. 2021: 41-42

View details for Web of Science ID 000693238000074